Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Parmiani

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
The Journal of Investigative Dermatology|April 9, 2010
Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cellsMichela Perego, Monica Tortoreto, Gabrina Tragni, et al.
The Lancet. Oncology|August 17, 2012
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialAnna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 25, 2013
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I moleculesRossana Tallerico, Matilde Todaro, Simone Di Franco, et al.
Cancer Research|May 3, 2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursorsTiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
Journal for Immunotherapy of Cancer|June 18, 2015
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyHubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptidesPaola Filipazzi, Lorenzo Pilla, Luigi Mariani, et al.
Gut|December 19, 2015
T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genesDaniele Mennonna, Cristina Maccalli, Michele C Romano, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
The Journal of Investigative Dermatology|April 9, 2010
Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cellsMichela Perego, Monica Tortoreto, Gabrina Tragni, et al.
The Lancet. Oncology|August 17, 2012
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialAnna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 25, 2013
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I moleculesRossana Tallerico, Matilde Todaro, Simone Di Franco, et al.
Cancer Research|May 3, 2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursorsTiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
Journal for Immunotherapy of Cancer|June 18, 2015
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyHubert Kübler, Birgit Scheel, Ulrike Gnad-Vogt, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Cancer Immunology, Immunotherapy : CII|October 11, 2005
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patientsLorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptidesPaola Filipazzi, Lorenzo Pilla, Luigi Mariani, et al.
Gut|December 19, 2015
T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genesDaniele Mennonna, Cristina Maccalli, Michele C Romano, et al.
Pageof 11